Private equity firms Matrix Capital and Surveyor Capital led a $137m Series funding round B round in VelosBio, a biotechnology company. Additional investors include Adage Capital Management, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management. “We are delighted to welcome a top-tier group of leading healthcare investors to advance development of our pipeline of first-in-class ROR1-directed therapeutics. We have made tremendous progress since founding the Company in 2017, and this financing reflects strong support for our platform, people, and comprehensive development strategy. This investment positions us to further the development of our unique pipeline of targeted therapies, and continue the expansion of our world-class team of scientists and researchers who share a passion for developing paradigm-shifting cancer therapeutics to improve patients’ lives," Dave Johnson, VelosBio CEO.